Navigation Links
Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
Date:9/2/2007

New approach for treatment of schizophrenia

INDIANAPOLIS, Sept. 2 /PRNewswire-FirstCall/ -- An investigational, phase II study published in the scientific journal Nature Medicine demonstrates that for the first time in humans a drug that acts on certain proteins in the brain called mGlu2/3 has antipsychotic activity. The study was sponsored by Eli Lilly and Company (NYSE: LLY).

In this study - a randomized, double-blind, placebo-controlled clinical trial - patients were assigned to four weeks of treatment with either Lilly's investigational compound LY2140023; olanzapine, an atypical antipsychotic medication that targets dopamine and serotonin receptors as an active control; or placebo. The study demonstrated that:

-- LY2140023 and olanzapine showed statistically significant improvement

versus placebo in PANSS (Positive and Negative Syndrome Scale), the

most common scale used for measuring symptoms of patients with

schizophrenia. Both groups showed a rapid response, within one week.

-- Treatment with LY2140023 was not observed to have certain adverse

events that often occur with currently approved schizophrenia

medications, including increased prolactin elevations, extrapyramidal

symptoms (involuntary movements or muscle stiffness), or weight gain.

-- Overall, LY2140023 40 mg given twice daily was found to be safe and

well-tolerated, with most adverse events being mild-to-moderate in

severity and not treatment-limiting.

"These data provide compelling new evidence that mGlu2/3 receptor agonists have antipsychotic properties and may provide a completely new therapeutic approach for treating schizophren
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. New Drug Application Submitted for Investigational Antibiotic Doripenem
2. Astrazenecas Investigational Cancer Therapies Revealed at ASCO
3. Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke
4. Novel Investigational Drug May Help American Women Suffering from Breast Pain
5. Effective And Economical Agent For Anthrax
6. New target for antidiabetic agents identified
7. Gold Nanoparticles: Agents For Noninvasive Cancer Therapy
8. A potent causative agent of dental flourosis: Fluoride
9. Another causative agent of adult onset asthma : Atopy
10. Revelation Of Cancer Agent Could Help In Developing Effective Cancer Drugs
11. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... Today, Zane Benefits, Inc. published ... insurance . Zane Benefits, which provides comprehensive and ... is the leader in health care reform, ... . , According to Zane Benefits’ website, many ... the value of small business health insurance for ...
(Date:5/19/2013)... Corpus Christi, TX (PRWEB) May 19, 2013 ... home security systems companies. Homeowners who are considering ... options and services of the nation's leading security system ... security systems reviews the best DIY home security ... results. Every year 6Webs.com reviews dozens of home security ...
(Date:5/19/2013)... Fat Burning Furnace developed by Rob ... people with fat burning diet plans, training ... Burning Furnace package, people will receive the Fat Burning ... quickly. The Fat Burning Furnace manual includes fat loss ... muscle mass. In addition, this book covers step-by-step instructions, ...
(Date:5/19/2013)... Farming methods have changed many times ... 10,000 years ago. Most recently, the Green Revolution has ... genetically engineered seeds and by applying chemical fertilizers and ... these techniques due to the adverse environmental and health ... surge in interest in organic, sustainable farming practices and ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Vegas Hotel ... is proud to announce the launch it's all new ... the MGM Grand on 5/19/2013. Consumers traveling to Las ... special pricing available on VegasHotelEscapes.com's website. Travelers will be ... beat any competitors price. , Vegas Hotel Escapes specializes ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Top Rated DIY Home Security System Companies Published by 6Webs.com 2Health News:Fat Burning Diet | How “Fat Burning Furnace” Helps People Lose Their Weight Naturally And Fast – V-kool 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3
... were women who also received training to manage the ... may seem best at preventing illness rather than treating ... activity could make an immediate difference for people with ... chronic pain syndrome who exercised moderately for four months ...
... University of Virginia clinical psychologists has found that teens who ... to exhibit delinquent behavior in early adulthood than their peers ... study also suggests that early sex may play a role ... adulthood., The finding is published in the current online edition ...
... Terms, quarterly report analyzes the information, needs that drove ... ... third quarter, NEW YORK, Nov. 12 ... ongoing series of quarterly reports intended to shed light on,the most ...
... Company Brings Global U.N. Environmental Initiative to ... its,commitment to sustainability and social responsibility, today ... up their sleeves, grabbed their spades and ... company announced that it has joined the ...
... on Striking Nurses, BECKLEY, W.Va., Nov. 12 ... Health Care (ARH), represented by,the Kentucky and West ... to call public attention to the underhanded and,violent ... their strike,which began Oct. 1. ARH has escalated ...
... eDiets.com,Inc. (Nasdaq: DIET ), leveraging the power ... consumers and businesses, today announced that it,has rescheduled ... report results for its third quarter ended September ... Wednesday, November 14, 2007 and,will host a conference ...
Cached Medicine News:Health News:Exercise Eases Fibromyalgia Symptoms: Study 2Health News:Exercise Eases Fibromyalgia Symptoms: Study 3Health News:Early teen sex may not be a path to delinquency, study shows 2Health News:SearchMedica.com Reveals Top Searches Among Medical Professionals 2Health News:SearchMedica.com Reveals Top Searches Among Medical Professionals 3Health News:Bayer Plants Trees With Chartiers Valley Intermediate School Students, Provides Free Environmental Education Materials 2Health News:Bayer Plants Trees With Chartiers Valley Intermediate School Students, Provides Free Environmental Education Materials 3Health News:Bayer Plants Trees With Chartiers Valley Intermediate School Students, Provides Free Environmental Education Materials 4Health News:Nurses Protest Violent Tactics Against Picketers 2Health News:eDiets.com(R) Updates Timing of Third Quarter 2007 Earnings Conference Call 2
(Date:5/17/2013)... , May 17, 2013 /PRNewswire-iReach/ -- The ... recombinant proteins, is placing renewed emphasis on alternate ... rise as a number of factors are converging ... pharmaceutical makers and their delivery device partners . ... refractory conditions, the growing trend toward self-administration for ...
(Date:5/17/2013)... -- Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ) a ... patent-pending technologies poised to redefine how consumers receive energy, medicines, ... business update teleconference and webcast for shareholders and the investment ... PM ET. Fuse Science, Inc. CEO, ... will be joined by Rubin Hanan , ...
(Date:5/17/2013)... 17, 2013  PENTAX Medical, a healthcare industry ... global leader in ultrasound imaging, recently announced renewed ... enable further innovation in the development of Endoscopic ... systems and PENTAX Medical endoscopic portfolio have formed ... EUS systems. This agreement will continue to grow ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3
... of Hypertension,s Twenty-Third ... Annual Scientific Meeting - A cumulative forty-five percent ... of BENICAR(R) (olmesartan medoxomil), and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) achieved ... normotension (< 120/80 mm Hg) (placebo:1.4%)., - Eight out of 10 (cumulative ...
... Florida and Scripps Research in La ... ... and LA JOLLA, Calif., May 14 /PRNewswire-,FirstCall/ -- Poniard Pharmaceuticals, Inc. ... Scripps Research,Institute, a non-profit biomedical research organization, today announced,that an agreement ...
Cached Medicine Technology:New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 2New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 3New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 4New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 5New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 7Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 3Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 4
Straight shafts with heavy Elschnig teeth. Flat serrated handle with slide style lock and polished finished....
Straight shafts with fine Pierse type tips. Flat smooth handle with dull finish....
Straight shafts with 1 x 2 Elsching style teeth. Wide serrated handle with polished finish....
Straight crisscross serrated tips. Flat handle with holes and polished finish....
Medicine Products: